Guardian Pharmacy Services, Inc. (GRDN) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GRDN Revenue Growth
Revenue Breakdown (FY 2025)
GRDN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
GRDN Revenue Analysis (2018–2025)
As of May 8, 2026, Guardian Pharmacy Services, Inc. (GRDN) generated trailing twelve-month (TTM) revenue of $1.46 billion, reflecting modest growth of +2.2% year-over-year. The most recent quarter (Q1 2026) recorded $336.6 million in revenue, down 15.3% sequentially.
Looking at the longer-term picture, GRDN's 5-year compound annual growth rate (CAGR) stands at +14.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $1.45 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows GRDN's business is primarily driven by Corporate Segment (100%). With over half of revenue concentrated in Corporate Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including OMCL (+7.9% YoY), PINC (-16.2% YoY), and CVS (+7.6% YoY), GRDN has underperformed the peer group in terms of revenue growth. Compare GRDN vs OMCL →
GRDN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GRDNCurrent | $1.5B | +2.2% | +14.5% | 6.1% | |
 OMCL | $1.2B | +7.9% | +5.8% | 0.4% | |
 PINC | $1.0B | -16.2% | -4.9% | 0.1% | |
 CVS | $402.1B | +7.6% | +8.4% | 2.6% | |
 CCRN | $1.1B | -39.5% | +4.7% | -0.3% | |
 MCK | $359.1B | +12.4% | +9.2% | 1.2% |
GRDN Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.45B | +17.9% | $282.0M | 19.5% | $88.9M | 6.1% |
| 2024 | $1.23B | +17.4% | $244.4M | 19.9% | $-62,920,000 | -5.1% |
| 2023 | $1.05B | +15.1% | $208.3M | 19.9% | $40.9M | 3.9% |
| 2022 | $908.9M | +14.8% | $185.9M | 20.4% | $52.0M | 5.7% |
| 2021 | $792.1M | +7.6% | $161.3M | 20.4% | $30.1M | 3.8% |
| 2020 | $736.0M | +5.4% | $147.0M | 20.0% | $32.1M | 4.4% |
| 2019 | $698.3M | +16.3% | $143.5M | 20.5% | $34.1M | 4.9% |
| 2018 | $600.4M | - | $123.0M | 20.5% | $25.9M | 4.3% |
See GRDN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRDN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GRDN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGRDN — Frequently Asked Questions
Quick answers to the most common questions about buying GRDN stock.
Is GRDN's revenue growth accelerating or slowing?
GRDN revenue growth slowed to +2.2%, below the 5-year CAGR of +14.5%. TTM revenue is $1.5B. The deceleration marks a shift from historical growth rates.
What is GRDN's long-term revenue growth rate?
Guardian Pharmacy Services, Inc.'s 5-year revenue CAGR of +14.5% reflects the variable expansion pattern. Current YoY growth of +2.2% is near this long-term average.
How is GRDN's revenue distributed by segment?
GRDN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.